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Genetic overlap and causal 
associations between smoking 
behaviours and mental health
Wikus Barkhuizen1,2, Frank Dudbridge3 & Angelica Ronald1*
Cigarette smoking is a modifiable behaviour associated with mental health. We investigated the 
degree of genetic overlap between smoking behaviours and psychiatric traits and disorders, and 
whether genetic associations exist beyond genetic influences shared with confounding variables 
(cannabis and alcohol use, risk-taking and insomnia). Second, we investigated the presence of causal 
associations between smoking initiation and psychiatric traits and disorders. We found significant 
genetic correlations between smoking and psychiatric disorders and adult psychotic experiences. 
When genetic influences on known covariates were controlled for, genetic associations between most 
smoking behaviours and schizophrenia and depression endured (but not with bipolar disorder or most 
psychotic experiences). Mendelian randomization results supported a causal role of smoking initiation 
on psychiatric disorders and adolescent cognitive and negative psychotic experiences, although not 
consistently across all sensitivity analyses. In conclusion, smoking and psychiatric disorders share 
genetic influences that cannot be attributed to covariates such as risk-taking, insomnia or other 
substance use. As such, there may be some common genetic pathways underlying smoking and 
psychiatric disorders. In addition, smoking may play a causal role in vulnerability for mental illness.
Tobacco smoking is a modifiable risk factor and despite declining rates of smoking, 14–15% of adults in the US 
and UK and 28% across Europe still smoke  regularly1–3. High co-occurrence between smoking behaviours and 
psychiatric disorders is well-established4–6. Smoking rates among individuals diagnosed with schizophrenia or 
bipolar disorder are five times greater and with depression two-fold greater compared to healthy  controls7,8. 
Smoking behaviours also co-occur with psychotic  experiences9–11, traits in the general population that typically 
resemble positive symptoms of psychotic disorders (e.g., paranoia, hallucinations and delusions). Smoking behav-
iours co-occur with  schizotypy12, a construct that has parallels with psychotic experiences and which assesses 
personality characteristics thought to reflect schizophrenia vulnerability. Regular smoking during adolescence 
has been associated with psychotic experiences and negative symptom traits (PENS) such as  anhedonia13.
In terms of underlying causes, shared genetic influences could explain the co-occurrence of smoking and 
psychiatric traits or disorders. A recent twin study found that regular smoking during adolescence shared genetic 
influences with paranoia and cognitive disorganization and familial influences with  hallucinations13. A previous 
study found no evidence that adolescent PENS were predicted by polygenic liability to initiate  smoking14 but used 
less well-powered genome-wide association study (GWAS) summary statistics than currently available. Schizo-
phrenia and major depression share genome-wide genetic influences with smoking  behaviours15,16, and polygenic 
liability to bipolar disorder has been associated with nicotine  dependence17. Genetic variants for smoking being 
identified in GWAS for schizophrenia could also indicate possible causal associations between these  traits18.
Several covariates could, at a genetic level, account for genetic overlap between psychiatric traits or disorders 
and smoking behaviour. Epidemiological studies have investigated cannabis and alcohol use, stressful or trau-
matic events, sociodemographic characteristics, novelty-seeking behaviour and sleep disturbances as covariates 
in the association between smoking and mental health  problems9–11,13,19–23. Risk-taking has also been associated 
with  smoking24,25 and psychiatric  outcomes26. Many of these covariates, including cannabis and alcohol use, 
risk-taking and insomnia, are partly under genetic influence and have been genetically associated with smoking 
or with psychiatric traits or  disorders27–32.
Smoking behaviour may be a causal risk factor for psychiatric disorders based on evidence from longitudi-
nal and dose–response associations and Mendelian randomization  studies19,21,23,33,34. Uncertainty remains over 
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whether smoking may be causally linked to psychotic experiences prior to the onset of psychiatric conditions 
or in individuals who may not meet diagnostic thresholds: The association between psychotic experiences and 
smoking is not fully explained by known confounding  factors9,35–39, (but  see35) and a dose–response relationship 
has been  reported9,40 although not  consistently35,38. Furthermore, most longitudinal studies report an associa-
tion between smoking and later reports of psychotic  experiences10,41–43 while adolescents do not appear to start 
smoking to alleviate pre-existing psychotic  experiences41. However, these observational studies cannot rule out 
the possibility that psychotic experiences were present prior to smoking initiation and vice-versa. Triangulation 
of longitudinal findings on the association between smoking and psychotic experiences with evidence from 
methods such as Mendelian randomization is needed.
In this study we employed a range of methods utilizing genetic data to systematically investigate the associa-
tion between smoking behaviours and psychotic experiences across adolescence and adulthood as well as with 
psychiatric disorders. We assessed the degree to which smoking behaviours are genetically correlated with major 
psychiatric disorders (schizophrenia, major depression and bipolar disorder), with psychotic experiences dur-
ing adolescence (paranoia and hallucinations, cognitive disorganization, anhedonia and negative symptoms), 
psychotic experiences in adults (auditory hallucinations, visual hallucinations, delusions of persecution and 
delusions of reference), and with schizotypy in adults (hypomania, perceptual aberrations, physical anhedonia 
and social anhedonia) after controlling for genetic overlap with cannabis and alcohol use, risk taking behaviour 
and sleep  disturbances27–31. Furthermore, we aimed to assess causal associations between smoking initiation and 
psychotic experiences across development and confirm previous reports of causal associations with psychiatric 
disorders.
Results
Conditional genetic overlap between smoking behaviours and mental health. Bivariate genetic 
correlations between smoking behaviours and psychotic experiences and psychiatric disorders are summarised 
in Fig. 1.
To investigate the degree to which these genetic correlations exist beyond genetic influences associated with 
covariates (lifetime cannabis use, alcohol consumption, insomnia and risk-taking behaviour), we specified 
genomic multiple regression models using Genomic Structural Equation Modelling (Genomic SEM)44. Models 
were run for phenotype pairs that shared at least nominally significant (p < 0.05) genetic overlap. Genetic cor-
relations between smoking behaviours and the covariates are shown in Supplementary Figure S1.
Figure 2 shows the path diagram between schizophrenia and smoking initiation to illustrate the specified 
covariance paths in the models (see Supplementary Figures S2-5 for path diagrams of all models). Table 1 
summarizes the conditional genetic correlations (bg) between smoking behaviours and psychiatric disorders/
psychotic experiences obtained from these models.
The genetic component of cigarettes per day, together with the genetic components of the four covariate 
predictors, accounted for 11–41% of genetic variation in psychiatric disorders and traits (calculated as one 
Figure 1.  Heat map showing genetic correlations between smoking behaviours, psychotic experiences and 
psychiatric disorders. PENS Psychotic experiences (PE) and negative symptom traits; NA indicates that genetic 
correlations could not be computed due to low SNP-heritability or sample size; *indicates statistically significant 
genetic correlations at p < .05; **indicates significance at FDR < .05 using Benjamini–Hochberg correction for 60 
tests; Genetic correlations reported using unconstrained LD score regression intercept between phenotypes with 
sample overlap (for example, smoking behaviour and major depression GWASs contained participants from the 
UK Biobank, and smoking behaviours and adolescent PENS contained participants from ALSPAC). Note that 
age of smoking initiation was coded in the direction of lower scores reflecting younger ages of initiation. Note 
that current smoking cases are current smokers (compared to ex-smokers).
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minus the residual variance shown in the figures). The equivalent values for smoking initiation, age of smoking 
initiation and current smoking status were 9–52%, 9–41%, and 11–41%, respectively.
Table 1 shows that after accounting for the genetic influences of the covariates, conditional genetic associa-
tions  (bg) were significant between cigarettes per day and schizophrenia (unattenuated compared to  rg estimates 
that did not account for covariates), depression (with  bg accounting for 53% of  rg; calculated as  bg/rg × 100) and 
adolescent anhedonia (unattenuated) but not with bipolar disorder, auditory hallucinations, visual hallucina-
tions and hypomania.
Significant conditional genetic associations were found between smoking initiation and depression, account-
ing for 42% of the  rg estimate from LD score regression. The conditional genetic association between smoking 
initiation and bipolar disorder was negative. This suggests that overlapping genetic influences of the covariates 
drove the positive genetic correlation observed in LD score regression. No genetic association was found between 
smoking initiation and schizophrenia, visual hallucinations, delusions of persecution, hypomania and adolescent 
cognitive disorganization after accounting for the genetic influences of covariates.
No significant conditional genetic associations were found between age of smoking initiation with schizo-
phrenia, depression, auditory hallucinations, visual hallucinations and hypomania. Negative conditional genetic 
association estimates indicate an association with a younger age of smoking initiation.
Significant genetic overlap not accounted for by other predictors in the model was found between current 
smoking and schizophrenia (with  bg being higher than the  rg estimate from LD score regression), depression 
(accounting for 79% of  rg) and visual hallucinations (74% of  rg) and not with auditory hallucinations. In sum-
mary, after controlling for genetic overlap with cannabis and alcohol use, insomnia and risk-taking behaviour, 
most smoking behaviours still showed significant genetic overlap with psychiatric disorders, but not with most 
measures of psychotic experiences.
Causal associations between smoking initiation and mental health. Table 2 presents the results 
from Mendelian randomization (MR; see also Supplementary Figures S6-13 and Supplementary Tables S2-4). 
All instrumental variables had a mean F > 10 indicating adequate strength of association with the exposures, and 
an  I2 > 0.9 and therefore MR-Egger sensitivity analyses can be considered reliable. Generalized summary-based 
Figure 2.  Path diagram illustrating genetic multiple regression models.  SmkInitg = Genetic component 
of smoking initiation;  CANg = Genetic component of cannabis use;  ALCg = Genetic component of alcohol 
consumption;  INSg = Genetic component of insomnia;  SCZg = Genetic component of schizophrenia; u = residual 
genetic variance;  bg = Conditional genetic correlation between the genetic components of smoking initiation and 
schizophrenia as summarized in Table 1; Double-headed arrow represents genetic covariance; Single-headed 
arrow represents regression paths; Path diagrams for models between all smoking behaviours and psychiatric 
phenotypes are provided in Supplementary Figures S2-5.
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Mendelian randomization (GSMR)45 and inverse-variance weighted Mendelian randomization (MR-IVW)46 
analyses yielded consistent results across analyses. These methods suggested a causal effect of smoking initiation 
on schizophrenia liability with this finding replicated in Weighted Median but not in MR-Egger or Weighted 
Mode sensitivity analyses, suggesting that results may have been biased due to violation of the instrumental vari-
able  assumptions47–49. A significant but smaller causal effect of schizophrenia liability on smoking initiation was 
also found, but the MR-Egger intercept was significantly different from zero (p = 0.043; Supplementary Table S2), 
indicating the presence of directional pleiotropy which could bias results from GSMR.
Evidence of a causal effect of smoking initiation on liability to major depression was found, and replicated 
in Weighted Median MR. However, this effect was not replicated in Weighted Mode MR and the GSMR effect 
size fell outside of the MR-Egger confidence intervals. Therefore, biased results due to violation of the instru-
mental variable assumptions cannot be ruled out. The MR-Egger intercept was significantly different from zero 
(p = 0.048), suggesting that results may have been affected by directional pleiotropy. No consistent evidence of a 
causal effect of depression liability on smoking initiation was detected.
Evidence of a causal effect of smoking initiation on liability for bipolar disorder was reported in GSMR and 
Weighted Median analyses with a similar effect size observed in MR-Egger, but not replicated in the Weighted 
Mode analysis. No evidence of reverse causation was found.
Evidence of a causal effect of smoking initiation on cognitive disorganisation was observed in GSMR and 
Weighted Median analyses. Effect sizes fell within the MR-Egger confidence intervals but was not replicated in 
Weighted Mode MR. We found a causal effect of smoking initiation on negative symptoms in the main MR analy-
sis, but this effect was not replicated in MR sensitivity analyses. No evidence of reverse causation was observed.
Table 1.  Conditional genetic correlations after accounting for genetic influences on covariates in genomic 
structural equation models. rg = Bivariate genetic correlation estimates calculated in LD score regression; 
 bg = Conditional genetic association estimates (accounting for genetic influences on cannabis and alcohol use, 
insomnia and risk taking) obtained from Genomic Structural Equasion Modelling that, in standardized form, 
can be interpreted as conditional genetic correlations accounting for genetic covariation between predictors 
and regression paths of covariates onto psychiatric outcomes; PE = Psychotic experiences; PENS = Psychotic 
experiences and negative symptom traits; p value thresholds for  bg set at 0.05 and displayed in bold text.




rg SE p bg SE p
Schizophrenia Cigarettes per day 0.13 0.02 2.27 ×  10–11 0.14 0.04 6.81 × 10–4
Schizophrenia Smoking initiation 0.19 0.02 2.69 ×  10–31 0.05 0.04 0.209
Schizophrenia Age of smoking initiation − 0.08 0.02 1.97 ×  10–5 − 0.03 0.04 0.434
Schizophrenia Current smoking 0.09 0.02 1.00 ×  10–4 0.16 0.05 8.17 × 10–4
Major depression Cigarettes per day 0.32 0.05 6.15 ×  10–12 0.17 0.06 0.003
Major depression Smoking initiation 0.38 0.03 1.57 ×  10–29 0.16 0.07 0.017
Major depression Age of smoking initiation − 0.33 0.04 1.16 ×  10–14 − 0.11 0.06 0.075
Major depression Current smoking 0.38 0.05 1.31 ×  10–14 0.30 0.07 1.93 × 10–5
Bipolar disorder Cigarettes per day 0.10 0.04 0.006 0.05 0.05 0.263
Bipolar disorder Smoking initiation 0.10 0.03 7.00 ×  10–4 − 0.11 0.05 0.029
Adult PE
Auditory hallucinations Cigarettes per day 0.28 0.12 0.015 0.05 0.12 0.662
Auditory hallucinations Age of smoking initiation − 0.25 0.12 0.037 0.00 0.12 0.999
Auditory hallucinations Current smoking 0.40 0.15 0.009 0.21 0.14 0.125
Visual hallucinations Cigarettes per day 0.33 0.09 4.00 ×  10–4 0.18 0.13 0.165
Visual hallucinations Smoking initiation 0.18 0.08 0.026 0.14 0.12 0.266
Visual hallucinations Age of smoking initiation − 0.31 0.10 0.002 − 0.15 0.13 0.248
Visual hallucinations Current smoking 0.35 0.11 0.001 0.26 0.13 0.044
Delusions of persecution Smoking initiation 0.32 0.13 0.015 0.20 0.18 0.258
Schizotypy
Hypomania Cigarettes per day 0.11 0.06 0.049 − 0.01 0.17 0.968
Hypomania Smoking initiation 0.17 0.05 8.00 ×  10–4 0.00 0.16 0.980
Hypomania Age of smoking initiation − 0.22 0.07 0.002 − 0.04 0.16 0.820
Adolescent PENS
Anhedonia Cigarettes per day 0.40 0.20 0.046 0.44 0.22 0.044
Cognitive disorganization Smoking initiation 0.39 0.16 0.017 0.09 0.22 0.676
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Discussion
This study aimed to investigate systematically the degree of overlapping common genetic influences between 
smoking behaviours and psychiatric traits and disorders across adolescence and adulthood. We found evidence 
of overlapping genetic influences at a genome-wide level between smoking behaviours and psychiatric disorders 
and with some psychotic experiences and negative symptom traits reported by adolescents and adults in the 
community. For schizophrenia and depression, the overlap in common genetic influences shown with smoking 
frequency and current smoking status remained after controlling for genetic influences on known covariates, 
namely cannabis use, alcohol use, risk taking and insomnia. Genetic associations between smoking behaviours 
and most positive psychotic experiences were explained by genetic influences shared with the covariates. We 
found evidence of causal effects of smoking initiation on adolescent cognitive and (to some degree) negative 
symptoms as well as on schizophrenia, depression and bipolar disorder. These findings hint at plausible pathways 
by which smoking during adolescence could be involved in the development of psychiatric disorders. However, 
evidence of causation should be considered moderate to weak because not all sensitivity analyses confirmed 
findings.
Our GSEM findings support the hypothesis that schizophrenia and depression share genetic pathways with 
smoking frequency and persistent smoking. This shared genetic aetiology may point toward common biological 
pathways such as those involving nicotine, the principal pharmacologically active component of smoking that acts 
as an agonist on the nicotinic acetylcholine receptor (nAChR). Variants within the CHRNA5‐A3‐B4 gene cluster 
which encodes for subunits of nAChR are among the most robust associations with nicotine  dependence50–53 and 
have also been implicated in  schizophrenia18. Presynaptic activation of nAChR stimulates the release of several 
neurotransmitters including dopamine, serotonin and  glutamate54–57. Dysregulation of dopaminergic and glu-
tamatergic pathways could both explain why some people may be more susceptible to the positive reinforcing 
effects of  smoking58 and have an increased vulnerability to develop  schizophrenia59.
We found support for a causal role of smoking initiation on liability to develop schizophrenia, depression and 
bipolar disorder, corroborating recent  findings33,34 whilst applying different Mendelian randomization methods. 
Compared to previous MR studies, we employed a method to remove likely pleiotropic variants from genetic 
instruments which aims to reduce confounding from biological pleiotropy. Despite this, not all sensitivity analy-
ses yielded consistent findings in our study, and therefore biased causal effect estimates due to pleiotropy or 
a proportion of invalid instruments cannot be ruled out. Interestingly, our GSEM findings indicated that the 
covariates accounted for genetic overlap between schizophrenia and smoking initiation, raising the possibility 
that these traits may be involved in causal pathways of smoking initiation on schizophrenia or that the Mendelian 
randomization methods may not have adequately controlled for pleiotropy. Our results of a possible causal effect 
of smoking initiation on schizophrenia and depression (and a small causal effect of schizophrenia on smoking 
initiation) concurs with meta-analytic findings of longitudinal  studies21,23. The action of nicotine on nAChR 
could underlie a mechanism by which smoking causally influences mental health. Chronic exposure to nicotine 
may result in long-lasting alterations of dopaminergic and cholinergic pathways, leading to an increase in risk of 
psychiatric  disorders60–62. Beyond nicotine, other toxic compounds released during combustion of tobacco cause 
neuro-inflammation and oxidative  stress63, factors that are associated with psychiatric  disorders64–66.
To our knowledge, this is the first study to report that genome-wide genetic influences on bipolar disorder 
overlap with those on smoking frequency and initiation. This finding supports recent evidence of an association 
between polygenic scores for bipolar disorder and nicotine  dependence17. Genetic overlap between bipolar disor-
der and smoking quantity was accounted for by genetic influences on the covariates. Interestingly, we found that 
genetic influences on smoking initiation was negatively associated with genetic influences on bipolar disorder 
after accounting for genetic overlap with the covariates, whereas the bivariate genetic correlation between these 
two phenotypes was positive. This negative genetic association was likely masked by overlapping genetic influ-
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Table 2.  Mendelian randomization results. GSMR, Generalized Summary-based Mendelian Randomization; 
MR-IVW, inverse-variance weighted Mendelian randomization; n SNPs, number of variants remaining in 
analyses after those identified as Heidi-outliers or with residual LD at  r2 > .1 were removed; PENS, psychotic 
experiences and negative symptom traits; SNPs identified as having residual LD and as Heidi outliers were also 
excluded from MR Egger, Weighted Median and Weighted Mode analyses; Bold text indicates significant p 
values at p < 0.05. a Summary statistics for smoking initiation excluded UK Biobank participants in analyses on 
major depression and adult psychotic experiences to avoid overlapping samples (N = 249,171).
7
Vol.:(0123456789)
Scientific Reports |        (2021) 11:14871  | https://doi.org/10.1038/s41598-021-93962-7
www.nature.com/scientificreports/
bipolar disorder is unlikely to explain causal pathways or may reflect complex pathways underlying multiple, 
related addiction, personality and psychiatric phenotypes.
Until recently, research into the genetic aetiology underlying the association between psychotic experiences 
in the community and smoking behaviours was lacking. Here, we report novel evidence that smoking behaviours 
share genetic influences with some types of psychotic experiences during adulthood (notably with visual and 
auditory hallucinations) and with hypomania. Interestingly, unlike our findings for schizophrenia and depression, 
the genetic overlap between most psychotic experiences and smoking was shared with the covariates. This sug-
gest that overlapping genome-wide genetic influences (captured by current GWASs) that act on both psychotic 
experiences and smoking behaviours are likely shared with co-occurring traits such as other substance use, sleep 
problems and risk taking, or mechanisms underlying these traits.
Our findings suggest that smoking may increase a propensity to experience cognitive and negative psychotic 
experiences during adolescence, although the association with negative symptom traits was not confirmed by 
sensitivity analyses. Our findings that smoking may cause early cognitive and negative symptoms during adoles-
cence could hint at developmental pathways by which smoking could increase the risk of developing psychiatric 
disorders. A recent preclinical study found that during adolescence, exposure to nicotine could lead to persistent 
alteration of neurotransmitter  pathways61 likely relevant to psychotic experiences. Smoking initiation and posi-
tive psychotic experiences in adulthood did not appear to be causally related. This is somewhat surprising given 
the known phenotypic association between psychotic experiences and psychiatric  disorders67–72 and could be 
explored further. Evidence suggests that psychotic experiences in adults have somewhat different underlying 
causal influences compared to psychotic experiences during  adolescence73 which may explain that lack of causal 
associations between smoking and psychotic experiences in later life. We also note that the GWASs on positive 
psychotic experiences were based on a small number of cases, which could have resulted in low power to detect 
causal effects in our study.
This study had limitations to be considered. In some genomic multiple regression models, the estimated 
residual variances were imprecise due to small GWAS sample sizes, particularly for schizotypy and adolescent 
PENS. To mitigate this, we performed GSEM models only for traits that had significant bivariate genetic cor-
relations. However, non-significant genetic correlations may have reflected smaller GWAS sample sizes rather 
than the absence of genetic overlap, and these analyses should be revisited once more powerful summary sta-
tistics become available. It is also possible that genetic influences on co-occurring factors other than those we 
considered (such as exposure to adverse life events or sociodemographic characteristics) could account for the 
genetic overlap between smoking and psychiatric disorders. Our Mendelian randomization analyses that used 
instruments from psychotic experiences summary statistics requires replication once better-powered GWASs 
for these psychiatric traits become available. We performed Mendelian randomization using instruments for 
smoking initiation, which has the advantage of being a trait measurable to the whole adolescent and adult popula-
tion (unlike number of cigarettes per day, which only applies to smokers). Nevertheless, it is noted that smoking 
initiation may partly pick up on traits such as risk taking or impulsivity. Future studies should consider using 
instruments for objective measures of smoking on samples stratified by smoking status to confirm our results. 
However, such designs have their own limitations since gene-environment interactions are likely (genes affecting 
tobacco consumption will only do so in those who took up smoking) and in such cases Mendelian randomization 
on stratified samples may introduce collider  bias74. Possible pleiotropic effects can be further investigated using 
multivariable Mendelian randomization, but GWASs with overlapping samples for exposures and confound-
ers (as was the case here) require additional adjustments and individual-level phenotypic data. The GWAS on 
smoking initiation included a small number of ALSPAC participants and overlapping samples may have inflated 
Mendelian randomization estimates in analyses with adolescent PENS. Despite our approach to exclude pos-
sible pleiotropic instruments from Mendelian randomization analyses, the sensitivity analyses indicated that we 
cannot rule out bias due to violation of the instrumental variable assumptions. Finally, results based on GWASs 
from large cohort and biobank studies may be affected by ascertainment bias.
In conclusion, there is genetic overlap between smoking behaviours and schizophrenia and depression, and 
we show it exists beyond genetic influences shared with other risk factors. Furthermore, smoking appears to play 
a role in the development of traits relating to mental illness during adolescence and our findings strengthen the 
evidence base for smoking as a causal risk associated with psychiatric disorders. Our study indicates that the 
mental health risks of smoking during adolescence require further investigation. Exploration of the biological 
links underlying smoking and psychiatric illness, and smoking interventions as part of mental health prevention 
strategies, are well-justified based on current evidence.
Methods
Samples and measures. Summary statistics for participants of European descent used in the analyses 
are presented in Table 3. Smoking  behaviours50 included smoking initiation, a binary phenotype with smok-
ers defined as those who reported having ever smoked regularly. The average number of cigarettes per day was 
assessed in current and former smokers, with never-smokers excluded. Age of smoking initiation was defined 
as the age at which current or former smokers started smoking regularly. Current smoking was assessed among 
smokers and coded as either current smokers or former smokers.
Summary statistics for adolescent PENS were obtained from a mega-GWAS of four continuous scales of PENS, 
assessed when participants were 15 to 19 years old. Ethical approval for the original adolescent PENS  GWAS75 was 
obtained for  TEDS76 from the Institute of Psychiatry ethics committee (ref: 05/Q0706/228), for  ALSPAC77,78 from 
the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees, and for  CATSS79 from the 
Karolinska Institute Ethical Review Board. All research participants and their parents granted informed consent.
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Summary statistics for schizotypy in  adulthood80,81 were available for four continuous schizotypy  scales82–84. 
Positive psychotic experiences in adults were assessed using four dichotomous items on lifetime occurrence. 
The average age of onset of psychotic experiences was 31.6 (s.d. = 17.6) years. Psychiatric disorders were defined 
based on standard diagnostic criteria and assessed during clinical interviews or obtained from health records 
and self-report16,85,86.
For covariates in genomic multiple regression, we selected phenotypes considered to be likely confounders of 
the association between smoking and psychotic experiences/psychiatric  disorders9–11,19–23 and for which GWAS 
summary statistics were available. Summary statistics were obtained for: cannabis  use32, a binary phenotype for 
whether participants had ever used cannabis; alcohol  consumption50, defined as average number of weekly drinks; 
risk taking was assessed with the item “Would you describe yourself as someone who takes risks?”; and insomnia 
defined as having trouble falling asleep at night or waking up in the middle of the  night27.
Additional details on summary statistics are provided in Supplementary Table S1 and the Supplementary 
Methods. The Birkbeck Department of Psychological Sciences’ Ethics Committee approved this study and all 
research was performed in accordance with institutional guidelines.
Analyses. Prior to analyses, single nucleotide polymorphisms (SNPs) with incomplete association statistics 
and strand ambiguous and non-biallelic SNPs were excluded. Variants were matched and allele orders harmo-
nized to the 1000 Genomes (phase 3) reference panel for European ancestry and restricted to HapMap 3 vari-
ants. Variants were excluded based on INFO scores < 0.9 and minor allele frequency (MAF) < 0.01. INFO scores 
were not provided in the summary statistics for smoking behaviours and drinks per week and were filtered on 
INFO < 0.3 by the study  authors50.
LD score regression. Genetic correlations  (rg) were estimated using linkage disequilibrium (LD) score 
 regression87,88 on a liability scale based on population prevalences of 1% for schizophrenia, 15% for major 
Table 3.  Summary statistics, phenotypes and sample sizes. GSCAN GWAS and Sequencing Consortium of 
Alcohol and Nicotine use, PENS psychotic experiences (PE) and negative symptom traits, TEDS Twins Early 
Development Study, ALSPAC Avon Longitudinal Study of Parents and Children, CATSS Child and Adolescent 
Twin Study in Sweden, PGC Psychiatric Genomics Consortium, ICC International Cannabis Consortium.
Phenotypes GWAS N SNP-h2 (SE) Samples
Smoking behaviour50
GSCAN
Smoking initiation 632,802 0.0885 (0.0029)
Cigarettes per day 263,954 0.0625 (0.0068)
Age of smoking initiation 262,990 0.0423 (0.0022)
Current smoking a 312,821 0.0490 (0.0028)
Adolescent PENS75
Meta-GWAS of  TEDS75 (mean age 16.32 years),  ALSPAC76,77 (mean age 16.76 years) and  CATSS78 (mean age 
18.31 years)
Paranoia and hallucinations 8665 − 0.0042 (0.0352)
Cognitive disorganization 6297 0.1048 (0.0566)
Anhedonia 6579 0.0797 (0.0479)
Negative symptoms 10,098 − 0.0222 (0.0316)
Schizotypy81
Northern Finland Birth Cohort 1996 (NFBC; at age 31 years)79
Hypomania 3967 0.3732 (0.1011)
Perceptual aberrations 4057 0.3037 (0.0916)
Physical anhedonia 3988 0.3655 (0.0965)
Social anhedonia 4025 0.2950 (0.0826)
Positive PE
UK Biobank (aged 40 – 69 years) obtained from the Neale Lab (http:// www. neale lab. is/ uk- bioba nk)
Auditory hallucinations 117,503 0.0709 (0.0255)
Visual hallucinations 116,787 0.1032 (0.0224)
Delusions of persecution 117,794 0.0910 (0.0521)
Delusions of reference 117,731 0.0666 (0.0499)
Psychiatric disorders
PGC (https:// www. med. unc. edu/ pgc/ resul ts- and- downl oads)
Schizophrenia85 105,318 0.2666 (0.0067)
Bipolar  disorder86 41,653 0.2999 (0.0102)
Major  Depression16 173,005 0.0999 (0.0042)
Covariates
Lifetime cannabis  use32 162,082 0.1880 (0.0082) ICC and UK Biobank
Alcohol  consumption50 537,349 0.0396 (0.0017) GSCAN
Risk taking (Neale Lab) 348,549 0.0560 (0.0018) UK Biobank
Insomnia27 113,006 0.0863 (0.0061) UK Biobank
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depression and 2% for bipolar  disorder89–91. Covariance intercepts were left unconstrained in analyses with over-
lapping samples (GWASs for smoking behaviours, depression and psychotic experiences in adults included UK 
Biobank participants; GWASs for smoking behaviours and adolescent PENS included ALSPAC participants). 
Correction for multiple testing (60 tests) was performed using Benjamini–Hochberg correction at a false dis-
covery rate (FDR) of 0.05.
Genomic structural equation modelling. To investigate genetic overlap between psychiatric phenotypes and 
smoking behaviours after accounting for the genetic influences on confounds, Genomic Structural Equation 
Modelling (Genomic SEM)44 was used to model shared genetic architecture using genetic covariance structures.
Summary statistics were converted to include LD scores in LD score regression software using the param-
eters described above. Genomic covariance structures were computed, and genomic multiple regression models 
specified in the Genomic SEM package for R version 3.5.292 for phenotype pairs that had nominally significant 
genetic correlations (at p < 0.05). Models allowed for genetic covariation between smoking phenotypes and the 
covariates included as predictors and regressed onto psychiatric outcomes. Standardized estimates were reported 
thereby allowing the association between a given predictor and each outcome to be interpreted as the genetic 
correlation conditional on all other predictors. Conditional genetic correlations were considered statistically 
significant at p < 0.05.
Mendelian randomization. Mendelian randomization (MR)93 was performed to test for bi-directional causal 
associations between smoking initiation and psychiatric phenotypes using summary statistics (see also Supple-
mentary Methods).
Generalised Summary-data-based Mendelian Randomisation (GSMR) was used as the main method due to 
its advantages of accounting for sampling variation in the exposure and outcome GWASs and for residual LD 
structure between variants used as instrumental variables (IVs)45. As a baseline to compare against sensitivity 
analyses, we also report MR-IVW46 results. MR-Egger regression, Weighted Median and Weighted Mode MR 
were conducted as sensitivity analyses as these methods make different assumptions to GSMR and MR-IVW by 
allowing for a proportion of invalid IVs in the  analyses47–49. To assess whether MR-Egger will be an appropriate 
sensitivity analysis, we computed the  I2 statistic, with  I2 > 0.9 indicating that MR-Egger results can be considered 
 reliable94. MR-Egger is typically less powerful to detect significant effects, but the MR-Egger confidence intervals 
are expected overlap with valid effect sizes from other methods. Directional pleiotropy was assessed using the 
MR-Egger intercept test. An intercept significantly different from zero indicates that MR-Egger causal estimates 
may be more robust compared to GSMR estimates. The strength of association between the IVs and exposures 
was assessed using the mean F-statistic, with F > 10 considered adequate instrument strength. Consistent find-
ings across MR methods indicates that results from GSMR are less likely to be biased due to violations of IV 
assumptions.
Summary statistics for major depression excluded 23andMe participants. To ensure at least 20 IVs were used, 
genome-wide significant variants were however obtained from the publication that did include the 23andMe 
 participants16. Major depression and adult psychotic experiences summary statistics included UK Biobank par-
ticipants. To avoid overlapping samples in these MR analyses, we used a version of the smoking initiation sum-
mary statistics that excluded UK Biobank participants (N = 249,171) and selected IVs at a p value threshold of 
5 ×  10–7, resulting in 20 independent depression variants to use as IVs in these MR analyses. Only seven variants 
reached genome-wide significance in the summary statistics for bipolar  disorder86. IVs for bipolar disorder were 
obtained from the publication of a recent meta-GWAS, also conducted on Psychiatric Genomics Consortium 
samples, but for which full summary statistics were not  available95. For all other exposures, IVs were identified 
using the clumping algorithm in  PLINK96 based on an  r2 threshold = 0.05 within a 500 kb window. Recent GWASs 
on psychotic experiences have not yet been replicated using equivalent measures in independent samples or have 
been based on relatively small sample sizes. Therefore, IVs for psychotic experiences were selected at p < 5 ×  10–5.
Analyses were performed in GSMR and MR Base R  packages45,97. GCTA 98 was used to calculate the LD 
structure between lead variants based on the 1000 Genomes (phase 3) reference panel for European ancestry. IVs 
excluded from GSMR analyses due to being Heidi-outliers and in residual LD at  r2 > 0.1 were also removed from 
MR sensitivity analyses. MR was conducted for smoking initiation but not for smoking phenotypes assessed in 
smokers only. This is because variant associations among smokers may not explain smoking liability in samples 
that include non-smokers. Smoking initiation is also temporally relevant to the adolescent PENS since most 
smokers initiate smoking during  adolescence99. Significance thresholds were set at p < 0.05.
Data and code availability
GWAS summary statistics used in the analyses for this paper are available at https:// atlas. ctglab. nl/ and at https:// 
www. med. unc. edu/ pgc/ downl oad- resul ts/. Summary data for adolescent psychotic experiences and for schizo-
typy were obtained from the authors with permission from the participating cohorts. Code to perform genomic 
structural equation modelling of GWAS summary statistics within Genomic SEM can be found at https:// github. 
com/ Miche lNiva rd/ Genom icSEM/ wiki. Code to perform the Mendelian randomization analyses is available at 
https:// cnsge nomics. com/ softw are/ gsmr/ and at https:// www. mrbase. org/.
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